Non-resolving, recurrent and chronic central serous chorioretinopathy: available treatment options.
Journal
Eye (London, England)
ISSN: 1476-5454
Titre abrégé: Eye (Lond)
Pays: England
ID NLM: 8703986
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
09
06
2018
accepted:
10
02
2019
revised:
30
01
2019
pubmed:
3
3
2019
medline:
28
10
2020
entrez:
3
3
2019
Statut:
ppublish
Résumé
Central serous chorioretinopathy is one of the most frequent causes of vision reduction among middle-aged men. This disease usually has a self-limiting course, but sometimes it lasts more than 4-6 months or a second episode follows a complete resolution of the first one. Nevertheless, to date no consensus exists about the duration threshold and therapy protocols for these non-resolving central serous chorioretinopathy. Treatment as half-dose and half-fluence photodynamic therapy, subthreshold micropulse laser treatment, mineralocorticoid receptor antagonists, intravitreal anti-angiogenic drugs, transpupillary thermal therapy, anti-androgenic drugs, methotrexate, Rifampicin and melatonin are described in this review. Complications are very uncommon but end-point results like central macular thickness reduction and best-corrected visual acuity improvement are difficult to compare among different therapeutic modalities due to different duration of follow-up and lack of homogeneity in patient recruitment. The aim of this review is focusing on treatment modalities for these chronic forms with comprehensive recent management updates according to latest clinical trial results. 摘要: 中心性浆液性脉络膜视网膜病变是导致中年男性视力下降最常见的原因之一。这种疾病通常具有自限性, 但有时它会持续4-6个月以上, 或在第一次治愈后复发。然而, 迄今为止, 人们对于这种难治性中心性浆液性脉络膜视网膜病变的时间阈值和治疗方案尚未达成共识。本文综述了半剂量、半效应光动力疗法、阈下微脉冲激光光凝治疗、盐皮质激素受体阻断剂、玻璃体内注入抗新生血管药物、经瞳孔温热疗法、抗雄激素药物、甲氨蝶呤、利福平、褪黑激素等治疗方法的疗效。以上几种治疗方法的并发症少见, 但由于随访时间不同和招募的患者缺乏同质性, 导致难以比较不同治疗方法下患者的黄斑中心凹厚度的减少和最佳矫正视力的提高等疗效。本综述的目的是根据最新的临床试验结果, 对这种慢性疾病的治疗方案的管理进行全面的更新。.
Autres résumés
Type: Publisher
(chi)
摘要: 中心性浆液性脉络膜视网膜病变是导致中年男性视力下降最常见的原因之一。这种疾病通常具有自限性, 但有时它会持续4-6个月以上, 或在第一次治愈后复发。然而, 迄今为止, 人们对于这种难治性中心性浆液性脉络膜视网膜病变的时间阈值和治疗方案尚未达成共识。本文综述了半剂量、半效应光动力疗法、阈下微脉冲激光光凝治疗、盐皮质激素受体阻断剂、玻璃体内注入抗新生血管药物、经瞳孔温热疗法、抗雄激素药物、甲氨蝶呤、利福平、褪黑激素等治疗方法的疗效。以上几种治疗方法的并发症少见, 但由于随访时间不同和招募的患者缺乏同质性, 导致难以比较不同治疗方法下患者的黄斑中心凹厚度的减少和最佳矫正视力的提高等疗效。本综述的目的是根据最新的临床试验结果, 对这种慢性疾病的治疗方案的管理进行全面的更新。.
Identifiants
pubmed: 30824822
doi: 10.1038/s41433-019-0381-7
pii: 10.1038/s41433-019-0381-7
pmc: PMC6707196
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Photosensitizing Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1035-1043Références
Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, et al. Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res. 2015;48:82–118.
doi: 10.1016/j.preteyeres.2015.05.003
pubmed: 26026923
Wang M, Munch IC, Hasler PW, Prunte C, Larsen M. Central serous chorioretinopathy. Acta Ophthalmol. 2008;86:126–45.
pubmed: 17662099
doi: 10.1111/j.1600-0420.2007.00889.x
Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002. Ophthalmology. 2008;115:169–73.
pubmed: 18166410
doi: 10.1016/j.ophtha.2007.02.032
Tsai DC, Chen SJ, Huang CC, Chou P, Chung CM, Huang PH, et al. Epidemiology of idiopathic central serous chorioretinopathy in Taiwan, 2001-2006: a population-based study. PLoS ONE. 2013;8:e66858.
pubmed: 23826160
pmcid: 3691239
doi: 10.1371/journal.pone.0066858
Chan WM, Lai TY, Tano Y, Liu DT, Li KK, Lam DS. Photodynamic therapy in macular diseases of asian populations: when East meets West. Jpn J Ophthalmol. 2006;50:161–9.
pubmed: 16604394
doi: 10.1007/s10384-005-0259-z
Lehmann M, Bousquet E, Beydoun T, Behar-Cohen F. PACHYCHOROID: an inherited condition? Retina. 2015;35:10–6.
doi: 10.1097/IAE.0000000000000287
pubmed: 25046398
Weenink AC, Borsje RA, Oosterhuis JA. Familial chronic central serous chorioretinopathy. Ophthalmologica. 2001;215:183–7.
pubmed: 11340388
doi: 10.1159/000050855
Gilbert CM, Owens SL, Smith PD, Fine SL. Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol. 1984;68:815–20.
pubmed: 6541945
pmcid: 1040477
doi: 10.1136/bjo.68.11.815
Gemenetzi M, De Salvo G, Lotery AJ. Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye (Lond). 2010;24:1743–56.
doi: 10.1038/eye.2010.130
Ross A, Ross AH, Mohamed Q. Review and update of central serous chorioretinopathy. Curr Opin Ophthalmol. 2011;22:166–73.
pubmed: 21427570
doi: 10.1097/ICU.0b013e3283459826
Miki A, Kondo N, Yanagisawa S, Bessho H, Honda S, Negi A. Common variants in the complement factor H gene confer genetic susceptibility to central serous chorioretinopathy. Ophthalmology. 2014;121:1067–72.
pubmed: 24365176
doi: 10.1016/j.ophtha.2013.11.020
Schubert C, Pryds A, Zeng S, Xie Y, Freund KB, Spaide RF, et al. Cadherin 5 is regulated by corticosteroids and associated with central serous chorioretinopathy. Hum Mutat. 2014;35:859–67.
pubmed: 24665005
pmcid: 4215937
doi: 10.1002/humu.22551
Tsai DC, Huang CC, Chen SJ, Chou P, Chung CM, Chan WL, et al. Central serous chorioretinopathy and risk of ischaemic stroke: a population-based cohort study. Br J Ophthalmol. 2012;96:1484–8.
pubmed: 22976583
doi: 10.1136/bjophthalmol-2012-301810
Carvalho-Recchia CA, Yannuzzi LA, Negrao S, Spaide RF, Freund KB, Rodriguez-Coleman H, et al. Corticosteroids and central serous chorioretinopathy. Ophthalmology. 2002;109:1834–7.
pubmed: 12359603
doi: 10.1016/S0161-6420(02)01117-X
Yannuzzi LA. Type A behavior and central serous chorioretinopathy. Retina. 2012;32(Suppl 1):709.
pubmed: 22451956
doi: 10.1097/IAE.0b013e31823ff9a6
Mansuetta CC, Mason JO 3rd, Swanner J, Feist RM, White MF Jr., Thomley ML, et al. An association between central serous chorioretinopathy and gastroesophageal reflux disease. Am J Ophthalmol. 2004;137:1096–100.
pubmed: 15183795
doi: 10.1016/j.ajo.2004.01.054
Bousquet E, Dhundass M, Lehmann M, Rothschild PR, Bayon V, Leger D, et al. Shift work: a risk factor for central serous chorioretinopathy. Am J Ophthalmol. 2016;165:23–8.
pubmed: 26915576
doi: 10.1016/j.ajo.2016.02.012
Matet A, Daruich A, Zola M, Behar-Cohen F. Risk factors for recurrences of central serous chorioretinopathy. Retina. 2017;38:1403–14.
doi: 10.1097/IAE.0000000000001729
Brodie FL, Charlson ES, Aleman TS, Salvo RT, Gewaily DY, Lau MK, et al. Obstructive sleep apnea and central serous chorioretinopathy. Retina. 2015;35:238–43.
pubmed: 25127049
pmcid: 5012108
doi: 10.1097/IAE.0000000000000326
Cheung CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund KB. Pachychoroid disease. Eye (Lond). 2019;33:18–33.
pubmed: 29995841
pmcid: 6328576
doi: 10.1038/s41433-018-0158-4
Warrow DJ, Hoang QV, Freund KB. Pachychoroid pigment epitheliopathy. Retina. 2013;33:1659–72.
doi: 10.1097/IAE.0b013e3182953df4
pubmed: 23751942
Pang CE, Freund KB. Pachychoroid pigment epitheliopathy may masquerade as acute retinal pigment epitheliitis. Invest Ophthalmol Vis Sci. 2014;55:5252.
doi: 10.1167/iovs.14-14959
pubmed: 25149971
Margolis R, Mukkamala SK, Jampol LM, Spaide RF, Ober MD, Sorenson JA, et al. The expanded spectrum of focal choroidal excavation. Arch Ophthalmol. 2011;129:1320–5.
doi: 10.1001/archophthalmol.2011.148
pubmed: 21670327
Balaratnasingam C, Lee WK, Koizumi H, Dansingani K, Inoue M, Freund KB. Polypoidal choroidal vasculopathy: a distinct disease or manifestation of many? Retina. 2016;36:1–8.
doi: 10.1097/IAE.0000000000000774
pubmed: 26414957
Spitznas M, Huke J. Number, shape, and topography of leakage points in acute type I central serous retinopathy. Graefes Arch Clin Exp Ophthalmol. 1987;225:437–40.
pubmed: 3678855
doi: 10.1007/BF02334172
Yang L, Jonas JB, Wei W. Optical coherence tomography-assisted enhanced depth imaging of central serous chorioretinopathy. Invest Ophthalmol Vis Sci. 2013;54:4659–65.
pubmed: 23737472
doi: 10.1167/iovs.12-10991
Piccolino FC, De La Longrais RR, Manea M, Cicinelli S. Posterior cystoid retinal degeneration in central serous chorioretinopathy. Retina. 2008;28:1008–12.
pubmed: 18698305
doi: 10.1097/IAE.0b013e31816b4b86
Lim Z, Wong D. Retinal pigment epithelial rip associated with idiopathic central serous chorioretinopathy. Eye (Lond). 2008;22:471–3.
doi: 10.1038/sj.eye.6703020
Ojima Y, Hangai M, Sasahara M, Gotoh N, Inoue R, Yasuno Y, et al. Three-dimensional imaging of the foveal photoreceptor layer in central serous chorioretinopathy using high-speed optical coherence tomography. Ophthalmology. 2007;114:2197–207.
pubmed: 17507096
doi: 10.1016/j.ophtha.2007.02.015
Quaranta-El Maftouhi M, El Maftouhi A, Eandi CM. Chronic central serous chorioretinopathy imaged by optical coherence tomographic angiography. Am J Ophthalmol. 2015;160:581–7. e1
pubmed: 26133250
doi: 10.1016/j.ajo.2015.06.016
Framme C, Walter A, Gabler B, Roider J, Sachs HG, Gabel VP. Fundus autofluorescence in acute and chronic-recurrent central serous chorioretinopathy. Acta Ophthalmol Scand. 2005;83:161–7.
pubmed: 15799726
doi: 10.1111/j.1600-0420.2005.00442.x
Zola M, Chatziralli I, Menon D, Schwartz R, Hykin P, Sivaprasad S. Evolution of fundus autofluorescence patterns over time in patients with chronic central serous chorioretinopathy. Acta Ophthalmol. 2018;96:e835–39.
pubmed: 29656602
doi: 10.1111/aos.13742
Eandi CM, Piccolino FC, Alovisi C, Tridico F, Giacomello D, Grignolo FM. Correlation between fundus autofluorescence and central visual function in chronic central serous chorioretinopathy. Am J Ophthalmol. 2015;159:652–8.
pubmed: 25555802
doi: 10.1016/j.ajo.2014.12.023
Yang L, Jonas JB, Wei W. Choroidal vessel diameter in central serous chorioretinopathy. Acta Ophthalmol. 2013;91:e358–62.
doi: 10.1111/aos.12059
pubmed: 23647989
Chan WM, Lai TY, Lai RY, Tang EW, Liu DT, Lam DS. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Retina. 2008;28:85–93.
doi: 10.1097/IAE.0b013e318156777f
pubmed: 18185143
Valmaggia C, Haueter I, Niederberger H. Photodynamic therapy in the treatment of persistent central serous chorioretinopathy: a two-year follow-up. Klin Monbl Augenheilkd. 2012;229:323–6.
pubmed: 22389262
doi: 10.1055/s-0031-1299263
Lim JI, Glassman AR, Aiello LP, Chakravarthy U, Flaxel CJ, Spaide RF, et al. Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology. 2014;121:1073–8.
doi: 10.1016/j.ophtha.2013.11.040
pubmed: 24439758
Ruiz-Del-Tiempo MP, Calvo P, Ferreras A, Lecinena J, Pablo L, Ruiz-Moreno O. Anatomical retinal changes after photodynamic therapy in chronic central serous chorioretinopathy. J Ophthalmol. 2018;2018:4081874.
pubmed: 29545952
pmcid: 5818899
doi: 10.1155/2018/4081874
Iacono P, Tedeschi M, Boccassini B, Chiaravalloti A, Varano M, Parravano M. Chronic central serous chorioretinopathy: early and late morphological and functional changes after verteporfin photodynamic therapy. Retina. 2018. https://doi.org/10.1097/IAE.0000000000002040 .
pubmed: 29346241
doi: 10.1097/IAE.0000000000002040
Inoue R, Sawa M, Tsujikawa M, Gomi F. Association between the efficacy of photodynamic therapy and indocyanine green angiography findings for central serous chorioretinopathy. Am J Ophthalmol. 2010;149:441–6. e1-2
pubmed: 20172070
doi: 10.1016/j.ajo.2009.10.011
Rouvas A, Stavrakas P, Theodossiadis PG, Stamatiou P, Milia M, Giannakaki E, et al. Long-term results of half-fluence photodynamic therapy for chronic central serous chorioretinopathy. Eur J Ophthalmol. 2012;22:417–22.
pubmed: 21928269
doi: 10.5301/ejo.5000051
Quin G, Liew G, Ho IV, Gillies M, Fraser-Bell S. Diagnosis and interventions for central serous chorioretinopathy: review and update. Clin Exp Ophthalmol. 2013;41:187–200.
pubmed: 22788713
doi: 10.1111/j.1442-9071.2012.02847.x
Ma J, Meng N, Xu X, Zhou F, Qu Y. System review and meta-analysis on photodynamic therapy in central serous chorioretinopathy. Acta Ophthalmol. 2014;92:e594–601.
doi: 10.1111/aos.12482
pubmed: 25042260
Hwang S, Kang SW, Kim SJ, Jang JW, Kim KT. Photodynamic therapy for symptomatic subfoveal retinal pigment epithelial detachment in central serous chorioretinopathy: outcomes and prognostic factors. Retina. 2018. https://doi.org/10.1097/IAE.0000000000002108 .
pubmed: 29517581
doi: 10.1097/IAE.0000000000002108
Maruko I, Iida T, Sugano Y, Ojima A, Ogasawara M, Spaide RF. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology. 2010;117:1792–9.
doi: 10.1016/j.ophtha.2010.01.023
pubmed: 20472289
Izumi T, Koizumi H, Maruko I, Takahashi Y, Sonoda S, Sakamoto T, et al. Structural analyses of choroid after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy. Br J Ophthalmol. 2017;101:433–7.
doi: 10.1136/bjophthalmol-2016-308921
pubmed: 27388248
Erikitola OC, Crosby-Nwaobi R, Lotery AJ, Sivaprasad S. Photodynamic therapy for central serous chorioretinopathy. Eye (Lond). 2014;28:944–57.
doi: 10.1038/eye.2014.134
Cheng CK, Chang CK, Peng CH. Comparison of photodynamic therapy using half-dose of verteporfin or half-fluence of laser light for the treatment of chronic central serous chorioretinopathy. Retina. 2017;37:325–33.
doi: 10.1097/IAE.0000000000001138
pubmed: 27429374
Nicolo M, Eandi CM, Alovisi C, Grignolo FM, Traverso CE, Musetti D, et al. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol. 2014;157:1033–7.
pubmed: 24487046
doi: 10.1016/j.ajo.2014.01.022
Lanzetta P, Furlan F, Morgante L, Veritti D, Bandello F. Nonvisible subthreshold micropulse diode laser (810 nm) treatment of central serous chorioretinopathy. A pilot study. Eur J Ophthalmol. 2008;18:934–40.
doi: 10.1177/112067210801800613
pubmed: 18988165
Khosla PK, Rana SS, Tewari HK, Azad RU, Talwar D. Evaluation of visual function following argon laser photocoagulation in central serous retinopathy. Ophthalmic Surg Lasers. 1997;28:693–7.
pubmed: 9269005
doi: 10.3928/1542-8877-19970801-16
Loo RH, Scott IU, Flynn HW Jr, Gass JD, Murray TG, Lewis ML, et al. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina. 2002;22:19–24.
pubmed: 11884873
doi: 10.1097/00006982-200202000-00004
Lim JW, Kang SW, Kim YT, Chung SE, Lee SW. Comparative study of patients with central serous chorioretinopathy undergoing focal laser photocoagulation or photodynamic therapy. Br J Ophthalmol. 2011;95:514–7.
pubmed: 20644214
doi: 10.1136/bjo.2010.182121
Lanzetta P, Dorin G, Pirracchio A, Bandello F. Theoretical bases of non-ophthalmoscopically visible endpoint photocoagulation. Semin Ophthalmol. 2001;16:8–11.
pubmed: 15487692
doi: 10.1076/soph.16.1.8.4216
Maruko I, Koizumi H, Hasegawa T, Arakawa H, Iida T. Subthreshold 577 nm micropulse laser treatment for central serous chorioretinopathy. PLoS ONE. 2017;12:e0184112.
pubmed: 28850595
pmcid: 5574536
doi: 10.1371/journal.pone.0184112
Scholz P, Altay L, Fauser S. A review of subthreshold micropulse laser for treatment of macular disorders. Adv Ther. 2017;34:1528–55.
pubmed: 28540655
pmcid: 5504253
doi: 10.1007/s12325-017-0559-y
Wood EH, Karth PA, Sanislo SR, Moshfeghi DM, Palanker DV. Nondamaging retinal laser therapy for treatment of central serous chorioretinopathy: what is the evidence? Retina. 2017;37:1021–33.
pubmed: 27841848
doi: 10.1097/IAE.0000000000001386
Mainster MA. Wavelength selection in macular photocoagulation. Tissue optics, thermal effects, and laser systems. Ophthalmology. 1986;93:952–8.
pubmed: 3763141
doi: 10.1016/S0161-6420(86)33637-6
Arsan A, Kanar HS, Sonmez A. Visual outcomes and anatomic changes after sub-threshold micropulse yellow laser (577-nm) treatment for chronic central serous chorioretinopathy: long-term follow-up. Eye (Lond). 2018;32:726–33.
doi: 10.1038/eye.2017.293
Ntomoka CG, Rajesh B, Muriithi GM, Goud A, Chhablani J. Comparison of photodynamic therapy and navigated microsecond laser for chronic central serous chorioretinopathy. Eye (Lond). 2018;32:1079–86.
doi: 10.1038/s41433-018-0029-z
van Dijk EHC, Fauser S, Breukink MB, Blanco-Garavito R, Groenewoud JMM, Keunen JEE, et al. Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial. Ophthalmology. 2018;125:1547–55.
pubmed: 29776672
doi: 10.1016/j.ophtha.2018.04.021
Roca JA, Wu L, Fromow-Guerra J, Rodriguez FJ, Berrocal MH, Rojas S, et al. Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group. Br J Ophthalmol. 2018;102:1696–1700.
pubmed: 29439089
doi: 10.1136/bjophthalmol-2017-311291
Golestaneh N, Picaud S, Mirshahi M. The mineralocorticoid receptor in rodent retina: ontogeny and molecular identity. Mol Vis. 2002;8:221–5.
pubmed: 12107409
Wilkinson-Berka JL, Tan G, Jaworski K, Miller AG. Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology. Circ Res. 2009;104:124–33.
pubmed: 19038868
doi: 10.1161/CIRCRESAHA.108.176008
Zhao M, Bousquet E, Valamanesh F, Farman N, Jeanny JC, Jaisser F, et al. Differential regulations of AQP4 and Kir4.1 by triamcinolone acetonide and dexamethasone in the healthy and inflamed retina. Invest Ophthalmol Vis Sci. 2011;52:6340–7.
pubmed: 21724913
doi: 10.1167/iovs.11-7675
Zhao M, Celerier I, Bousquet E, Jeanny JC, Jonet L, Savoldelli M, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Investig. 2012;122:2672–9.
pubmed: 22684104
doi: 10.1172/JCI61427
pmcid: 3386817
van Dijk EH, Nijhoff MF, de Jong EK, Meijer OC, de Vries AP, Boon CJ. Central serous chorioretinopathy in primary hyperaldosteronism. Graefes Arch Clin Exp Ophthalmol. 2016;254:2033–42.
pubmed: 27393297
pmcid: 5045484
doi: 10.1007/s00417-016-3417-8
Ghadiali Q, Jung JJ, Yu S, Patel SN, Yannuzzi LA. Central serous chorioretinopathy treated with mineralocorticoid antagonists: a one-year pilot study. Retina. 2016;36:611–8.
doi: 10.1097/IAE.0000000000000748
pubmed: 26405766
Cakir B, Fischer F, Ehlken C, Buhler A, Stahl A, Schlunck G, et al. Clinical experience with eplerenone to treat chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2016;254:2151–7.
pubmed: 27145785
doi: 10.1007/s00417-016-3373-3
Daruich A, Matet A, Dirani A, Gallice M, Nicholson L, Sivaprasad S, et al. Oral mineralocorticoid-receptor antagonists: real-life experience in clinical subtypes of nonresolving central serous chorioretinopathy with chronic epitheliopathy. Transl Vis Sci Technol. 2016;5:2.
pubmed: 26966638
pmcid: 4782825
doi: 10.1167/tvst.5.2.2
Schwartz R, Habot-Wilner Z, Martinez MR, Nutman A, Goldenberg D, Cohen S, et al. Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study. Acta Ophthalmol. 2017;95:e610–e8.
doi: 10.1111/aos.13491
pubmed: 28653813
Rahimy E, Pitcher JD 3rd, Hsu J, Adam MK, Shahlaee A, Samara WA, et al. A randomized double-blind placebo-control pilot study of eplerenone for the treatment of central serous chorioretinopathy (Ecselsior). Retina. 2018;38:962–9.
pubmed: 28426624
doi: 10.1097/IAE.0000000000001649
van Dijk EHC, Schellevis RL, van Bergen M, Breukink MB, Altay L, Scholz P, et al. Association of a haplotype in the NR3C2 gene, encoding the mineralocorticoid receptor, with chronic central serous chorioretinopathy. JAMA Ophthalmol. 2017;135:446–51.
pubmed: 28334414
pmcid: 5847108
doi: 10.1001/jamaophthalmol.2017.0245
Shin MC, Lim JW. Concentration of cytokines in the aqueous humor of patients with central serous chorioretinopathy. Retina. 2011;31:1937–43.
pubmed: 21478806
doi: 10.1097/IAE.0b013e31820a6a17
Lim JW, Kim MU, Shin MC. Aqueous humor and plasma levels of vascular endothelial growth factor and interleukin-8 in patients with central serous chorioretinopathy. Retina. 2010;30:1465–71.
pubmed: 20526231
doi: 10.1097/IAE.0b013e3181d8e7fe
Ji S, Wei Y, Chen J, Tang S. Clinical efficacy of anti-VEGF medications for central serous chorioretinopathy: a meta-analysis. Int J Clin Pharm. 2017;39:514–21.
pubmed: 28386700
doi: 10.1007/s11096-017-0460-4
Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol. 2007;143:977–83.
pubmed: 17459318
doi: 10.1016/j.ajo.2007.02.039
Bandello F, Virgili G, Lanzetta P, Pirracchio A, Menchini U. [ICG angiography and retinal pigment epithelial decompensation (CRSC and epitheliopathy)]. J Fr Ophtalmol. 2001;24:448–51.
pubmed: 11351219
Fung AT, Yannuzzi LA, Freund KB. Type 1 (sub-retinal pigment epithelial) neovascularization in central serous chorioretinopathy masquerading as neovascular age-related macular degeneration. Retina. 2012;32:1829–37.
doi: 10.1097/IAE.0b013e3182680a66
pubmed: 22850219
Peiretti E, Caminiti G, Serra R, Querques L, Pertile R, Querques G. Anti-Vegf therapy versus photodynamic therapy in the treatment of choroidal neovascularization secondary to central serous chorioretinopathy. Retina. 2017;3:1526–32.
Shukla D, Kolluru C, Vignesh TP, Karthikprakash S, Kim R. Transpupillary thermotherapy for subfoveal leaks in central serous chorioretinopathy. Eye (Lond). 2008;22:100–6.
doi: 10.1038/sj.eye.6702449
Hussain N, Khanna R, Hussain A, Das T. Transpupillary thermotherapy for chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2006;244:1045–51.
pubmed: 16411109
doi: 10.1007/s00417-005-0175-4
Mathur V, Parihar J, Maggon R, Mishra SK. Role of transpupillary thermotherapy in central serous chorio-retinopathy. Med J Armed Forces India. 2009;65:323–7.
pubmed: 27408285
pmcid: 4921371
doi: 10.1016/S0377-1237(09)80092-0
Manayath GJ, Narendran V, Arora S, Morris RJ, Saravanan VR, Shah PK. Graded subthreshold transpupillary thermotherapy for chronic central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging. 2012;43:284–90.
pubmed: 22788581
doi: 10.3928/15428877-20120618-06
Manayath GJ, Karandikar SS, Narendran S, Kumarswamy KA, Saravanan VR, Morris RJ, et al. Low fluence photodynamic therapy versus graded subthreshold transpupillary thermotherapy for chronic central serous chorioretinopathy: results from a prospective study. Ophthalmic Surg Lasers Imaging Retina. 2017;48:334–8.
pubmed: 28419399
doi: 10.3928/23258160-20170329-08
Nudleman E, Witmer MT, Kiss S, Williams GA, Wolfe JD. Central serous chorioretinopathy in patients receiving exogenous testosterone therapy. Retina. 2014;34:2128–32.
pubmed: 24946102
doi: 10.1097/IAE.0000000000000198
Grieshaber MC, Staub JJ, Flammer J. The potential role of testosterone in central serous chorioretinopathy. Br J Ophthalmol. 2007;91:118–9.
pubmed: 17179128
pmcid: 1857578
doi: 10.1136/bjo.2006.098277
Ahad MA, Chua CN, Evans NM. Central serous chorioretinopathy associated with testosterone therapy. Eye (Lond). 2006;20:503–5.
doi: 10.1038/sj.eye.6701905
Grino PB, Griffin JE, Wilson JD. Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology. 1990;126:1165–72.
pubmed: 2298157
doi: 10.1210/endo-126-2-1165
Forooghian F, Meleth AD, Cukras C, Chew EY, Wong WT, Meyerle CB. Finasteride for chronic central serous chorioretinopathy. Retina. 2011;31:766–71.
pubmed: 21273946
pmcid: 3116973
doi: 10.1097/IAE.0b013e3181f04a35
Moisseiev E, Holmes AJ, Moshiri A, Morse LS. Finasteride is effective for the treatment of central serous chorioretinopathy. Eye (Lond). 2016;30:850–6.
doi: 10.1038/eye.2016.53
Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:423–36.
pubmed: 15170445
doi: 10.1038/nrc1369
Munoz R, Shaked Y, Bertolini F, Emmenegger U, Man S, Kerbel RS. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy. Breast. 2005;14:466–79.
pubmed: 16199161
doi: 10.1016/j.breast.2005.08.026
Kurup SK, Oliver A, Emanuelli A, Hau V, Callanan D. Low-dose methotrexate for the treatment of chronic central serous chorioretinopathy: a retrospective analysis. Retina. 2012;32:2096–101.
pubmed: 22718154
doi: 10.1097/IAE.0b013e31825dd281
Shichiri M, Fukai N, Kono Y, Tanaka Y. Rifampicin as an oral angiogenesis inhibitor targeting hepatic cancers. Cancer Res. 2009;69:4760–8.
pubmed: 19458074
doi: 10.1158/0008-5472.CAN-08-3417
Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol. 1999;39:1–17.
pubmed: 10331074
doi: 10.1146/annurev.pharmtox.39.1.1
Shulman S, Goldenberg D, Schwartz R, Habot-Wilner Z, Barak A, Ehrlich N, et al. Oral Rifampin treatment for longstanding chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2016;254:15–22.
pubmed: 25794988
doi: 10.1007/s00417-015-2989-z
Pandi-Perumal SR, Trakht I, Spence DW, Srinivasan V, Dagan Y, Cardinali DP. The roles of melatonin and light in the pathophysiology and treatment of circadian rhythm sleep disorders. Nat Clin Pract Neurol. 2008;4:436–47.
pubmed: 18628753
doi: 10.1038/ncpneuro0847
Lissoni P, Rovelli F, Malugani F, Bucovec R, Conti A, Maestroni GJ. Anti-angiogenic activity of melatonin in advanced cancer patients. Neuro Endocrinol Lett. 2001;22:45–7.
pubmed: 11335879
Siu AW, Maldonado M, Sanchez-Hidalgo M, Tan DX, Reiter RJ. Protective effects of melatonin in experimental free radical-related ocular diseases. J Pineal Res. 2006;40:101–9.
pubmed: 16441546
doi: 10.1111/j.1600-079X.2005.00304.x
Esposito E, Cuzzocrea S. Antiinflammatory activity of melatonin in central nervous system. Curr Neuropharmacol. 2010;8:228–42.
pubmed: 21358973
pmcid: 3001216
doi: 10.2174/157015910792246155
Shi D, Xiao X, Wang J, Liu L, Chen W, Fu L, et al. Melatonin suppresses proinflammatory mediators in lipopolysaccharide-stimulated CRL1999 cells via targeting MAPK, NF-kappaB, c/EBPbeta, and p300 signaling. J Pineal Res. 2012;53:154–65.
pubmed: 22348531
doi: 10.1111/j.1600-079X.2012.00982.x
Gramajo AL, Marquez GE, Torres VE, Juarez CP, Rosenstein RE, Luna JD, et al. Therapeutic benefit of melatonin in refractory central serous chorioretinopathy. Eye (Lond). 2015;29:1036–45.
doi: 10.1038/eye.2015.104